Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.
The kinetics of cytotoxicity induced by ricin and a series of immunotoxins consisting of ricin A-chain coupled to antibodies against cell-surface antigens has been studied. The inhibition of protein synthesis in cells treated with immunotoxins or ricin occurs after a lag period. The rate of protein synthesis decreases according to a mono-exponential function, indicating a first-order process. With increasing concentration of immunotoxin, a maximal rate of inhibition is reached. The inactivation rate induced by immunotoxins was much slower than that achieved with ricin, even when products were compared on a basis of an identical number of molecules bound per cell, demonstrating the real higher efficacy of ricin. The time required to reduce protein synthesis by 90%, denoted T10, was 1.4-1.6 h with ricin, 60 h with anti-T65 immunotoxin on CEM human T leukemia cells (T65 positive), 65 h with anti-p97 immunotoxin on SK-MEL 28 human melanoma cells (p97 positive), and 20 h with an IgM anti-Thy 1.2 immunotoxin on WEHI-7 mouse T leukemia cells (Thy 1.2 positive). In this latter case, when the IgM antibody was replaced by an IgG anti-Thy 1.2, a 5-fold increase in the inactivation rate was obtained, demonstrating the importance of the binding moiety for the immunotoxins. Lysosomotropic amines such as ammonium chloride, chloroquine, and methylamine and carboxylic ionophores such as monensin, which are known to interfere with the uptake of certain macromolecules, strongly increased the rate of protein synthesis inhibition by all immunotoxins tested and increased 4-50,000-fold the sensitivity of cells to the immunotoxin. Enhancement in the inactivation rate was as much as 7-10-fold when either of these compounds was added, generating T10 values comparable to those of ricin.
D000588:Amines / Q000494:pharmacology*; D000643:Ammonium Chloride / Q000494:pharmacology; D000818:Animals; D000954:Antigens, Surface / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007476:Ionophores / Q000494:pharmacology*; D007518:Isoantibodies / Q000276:immunology; D007700:Kinetics; D007942:Leukemia, Experimental / Q000276:immunology; D007976:Leupeptins / Q000494:pharmacology; D051379:Mice; D008985:Monensin / Q000494:pharmacology; D009550:Nigericin / Q000494:pharmacology; D010436:Pepstatins / Q000494:pharmacology; D014176:Protein Biosynthesis; D012276:Ricin / Q000276:immunology*
D000588:Amines; D000954:Antigens, Surface; D007476:Ionophores; D007518:Isoantibodies; D007976:Leupeptins; D010436:Pepstatins; C035678:anti-Thy antibody; D000643:Ammonium Chloride; C014195:Streptomyces pepsin inhibitor; D012276:Ricin; D008985:Monensin; C032854:leupeptin; D009550:Nigericin; C031375:pepstatin